Date posted 21 May 2020
Event date 12 June 2020
The current COVID-19 pandemic raises critical clinical questions and challenges for health professionals seeking to continue optimal care for patients with cancer. The VCCC is pleased to partner with the Monash Partners Comprehensive Cancer Consortium (MPCCC) to present the next special COVID-19 and cancer in Victoria series.
Australia’s response to the COVID-19 pandemic compared to the rest of the world puts our medical research and health sector in a unique position, not least our clinical trial units.
Australia, and particularly Victoria, has an excellent reputation for delivering world-class clinical trials. Throughout the pandemic, clinical trial units have had to be agile, changing practices to ensure patient safety; closing some trials, conducting others via telehealth or moving patients to standard care.
The Victorian clinical trials sector is now preparing to re-open and increase recruitment; potential opportunities include engaging with new research areas, providing special services and attracting increased trial activity.
Professor Mark Rosenthal, VCCC Clinical Trials Development Lead and Director, Parkville Cancer Clinical Trials Unit moderates this discussion on Victoria’s clinical trials sector progress development and taking advantage of opportunities after the pandemic shutdown.
How has the Victorian clinical trials sector been impacted by the pandemic?
What are the opportunities for the Victorian clinical trials sector now and in the future?
Moderator and presentation speakers are joined by:
Manager Cancer Research, Bendigo Cancer Centre
Professor Nikolajs Zeps
Group Director of Research and Development